Clínic Barcelona

An initial combined treatment for pulmonary arterial hypertension provides better long-term results

A study published in the New England Journal of Medicine (NEJM) shows that the combination of two drugs (ambrisentan and tadalafil) is more effective than the use of one of these agents to treat pulmonary arterial hypertension. The combination therapy improves very significantly the outcome of patients with this disease and reduces by 50% the risk of clinical failure. Dr. Joan Albert Barberà, pulmonologist at Hospital Clínic and head of the IDIBAPS team Physiopathological mechanisms of respiratory illnesses is one of the authors of this study and coordinator of the trial in Spain.